APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Diabetes Medicines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Diabetes Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173984070329 December 2025193 pages

Choose your research edition.

Industry ResearchDiabetes Medicines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetes Medicines Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Diabetes Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetes Medicines Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetes Medicines Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Diabetes Medicines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Diabetes Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetes Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetes Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Diabetes Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diabetes Medicines include Biocon, Boehringer Ingelheim, Geropharm, Wockhardt, AstraZeneca, bayer, Ganli Pharmaceutical, Jiangsu Wanbang and Conker Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diabetes Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetes Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetes Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diabetes Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.

Diabetes Medicines Segment by Company

Biocon

Boehringer Ingelheim

Geropharm

Wockhardt

AstraZeneca

bayer

Ganli Pharmaceutical

Jiangsu Wanbang

Conker Pharmaceuticals

Eli Lilly

United Pharmaceuticals

Merck Serono

Merck

Novo Nordisk

Novartis

Johnson & Johnson

Sanofi

Tonghua Dongbao

Takeda

Diabetes Medicines Segment by Type

Oral

Injection

Diabetes Medicines Segment by Application

Hospital

Retail Pharmacy

Diabetes Medicines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetes Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Medicines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diabetes Medicines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diabetes Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Diabetes Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Diabetes Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Diabetes Medicines Industry Trends Table 2. Diabetes Medicines Industry Drivers Table 3. Diabetes Medicines Industry Opportunities and Challenges Table 4. Diabetes Medicines Industry Restraints Table 5. Global Diabetes Medicines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Diabetes Medicines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Diabetes Medicines Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Diabetes Medicines Sales Market Share by Manufacturers Table 9. Global Diabetes Medicines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Diabetes Medicines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Diabetes Medicines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Diabetes Medicines Manufacturers, Product Type & Application Table 13. Global Diabetes Medicines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Diabetes Medicines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Global Diabetes Medicines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Diabetes Medicines Sales by Type (2021-2026) & (K Units) Table 20. Global Diabetes Medicines Sales by Type (2027-2032) & (K Units) Table 21. Global Diabetes Medicines Sales Market Share by Type (2021-2026) Table 22. Global Diabetes Medicines Sales Market Share by Type (2027-2032) Table 23. Global Diabetes Medicines Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Diabetes Medicines Revenue by Type (2021-2026) & (K Units) Table 25. Global Diabetes Medicines Revenue by Type (2027-2032) & (K Units) Table 26. Global Diabetes Medicines Revenue Market Share by Type (2021-2026) Table 27. Global Diabetes Medicines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Retail Pharmacy Table 30. Global Diabetes Medicines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Diabetes Medicines Sales by Application (2021-2026) & (K Units) Table 32. Global Diabetes Medicines Sales by Application (2027-2032) & (K Units) Table 33. Global Diabetes Medicines Sales Market Share by Application (2021-2026) Table 34. Global Diabetes Medicines Sales Market Share by Application (2027-2032) Table 35. Global Diabetes Medicines Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Diabetes Medicines Revenue by Application (2021-2026) & (K Units) Table 37. Global Diabetes Medicines Revenue by Application (2027-2032) & (K Units) Table 38. Global Diabetes Medicines Revenue Market Share by Application (2021-2026) Table 39. Global Diabetes Medicines Revenue Market Share by Application (2027-2032) Table 40. Global Diabetes Medicines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Diabetes Medicines Sales by Region (2021-2026) & (K Units) Table 42. Global Diabetes Medicines Sales Market Share by Region (2021-2026) Table 43. Global Diabetes Medicines Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Diabetes Medicines Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Diabetes Medicines Sales by Country (2021-2026) & (K Units) Table 47. North America Diabetes Medicines Sales by Country (2027-2032) & (K Units) Table 48. Europe Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Diabetes Medicines Sales by Country (2021-2026) & (K Units) Table 50. Europe Diabetes Medicines Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Diabetes Medicines Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Diabetes Medicines Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Diabetes Medicines Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Diabetes Medicines Sales by Country (2027-2032) & (K Units) Table 57. Global Diabetes Medicines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Diabetes Medicines Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Diabetes Medicines Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Diabetes Medicines Revenue Market Share by Region (2021-2026) Table 61. Global Diabetes Medicines Revenue Market Share by Region (2027-2032) Table 62. Biocon Company Information Table 63. Biocon Business Overview Table 64. Biocon Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Biocon Diabetes Medicines Product Portfolio Table 66. Biocon Recent Development Table 67. Boehringer Ingelheim Company Information Table 68. Boehringer Ingelheim Business Overview Table 69. Boehringer Ingelheim Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Boehringer Ingelheim Diabetes Medicines Product Portfolio Table 71. Boehringer Ingelheim Recent Development Table 72. Geropharm Company Information Table 73. Geropharm Business Overview Table 74. Geropharm Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Geropharm Diabetes Medicines Product Portfolio Table 76. Geropharm Recent Development Table 77. Wockhardt Company Information Table 78. Wockhardt Business Overview Table 79. Wockhardt Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Wockhardt Diabetes Medicines Product Portfolio Table 81. Wockhardt Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AstraZeneca Diabetes Medicines Product Portfolio Table 86. AstraZeneca Recent Development Table 87. bayer Company Information Table 88. bayer Business Overview Table 89. bayer Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. bayer Diabetes Medicines Product Portfolio Table 91. bayer Recent Development Table 92. Ganli Pharmaceutical Company Information Table 93. Ganli Pharmaceutical Business Overview Table 94. Ganli Pharmaceutical Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Ganli Pharmaceutical Diabetes Medicines Product Portfolio Table 96. Ganli Pharmaceutical Recent Development Table 97. Jiangsu Wanbang Company Information Table 98. Jiangsu Wanbang Business Overview Table 99. Jiangsu Wanbang Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Jiangsu Wanbang Diabetes Medicines Product Portfolio Table 101. Jiangsu Wanbang Recent Development Table 102. Conker Pharmaceuticals Company Information Table 103. Conker Pharmaceuticals Business Overview Table 104. Conker Pharmaceuticals Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Conker Pharmaceuticals Diabetes Medicines Product Portfolio Table 106. Conker Pharmaceuticals Recent Development Table 107. Eli Lilly Company Information Table 108. Eli Lilly Business Overview Table 109. Eli Lilly Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Eli Lilly Diabetes Medicines Product Portfolio Table 111. Eli Lilly Recent Development Table 112. United Pharmaceuticals Company Information Table 113. United Pharmaceuticals Business Overview Table 114. United Pharmaceuticals Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. United Pharmaceuticals Diabetes Medicines Product Portfolio Table 116. United Pharmaceuticals Recent Development Table 117. Merck Serono Company Information Table 118. Merck Serono Business Overview Table 119. Merck Serono Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Merck Serono Diabetes Medicines Product Portfolio Table 121. Merck Serono Recent Development Table 122. Merck Company Information Table 123. Merck Business Overview Table 124. Merck Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Merck Diabetes Medicines Product Portfolio Table 126. Merck Recent Development Table 127. Novo Nordisk Company Information Table 128. Novo Nordisk Business Overview Table 129. Novo Nordisk Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Novo Nordisk Diabetes Medicines Product Portfolio Table 131. Novo Nordisk Recent Development Table 132. Novartis Company Information Table 133. Novartis Business Overview Table 134. Novartis Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Novartis Diabetes Medicines Product Portfolio Table 136. Novartis Recent Development Table 137. Johnson & Johnson Company Information Table 138. Johnson & Johnson Business Overview Table 139. Johnson & Johnson Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Johnson & Johnson Diabetes Medicines Product Portfolio Table 141. Johnson & Johnson Recent Development Table 142. Sanofi Company Information Table 143. Sanofi Business Overview Table 144. Sanofi Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Sanofi Diabetes Medicines Product Portfolio Table 146. Sanofi Recent Development Table 147. Tonghua Dongbao Company Information Table 148. Tonghua Dongbao Business Overview Table 149. Tonghua Dongbao Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Tonghua Dongbao Diabetes Medicines Product Portfolio Table 151. Tonghua Dongbao Recent Development Table 152. Takeda Company Information Table 153. Takeda Business Overview Table 154. Takeda Diabetes Medicines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Takeda Diabetes Medicines Product Portfolio Table 156. Takeda Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Diabetes Medicines Distributors List Table 160. Diabetes Medicines Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Diabetes Medicines Product Image Figure 2. Global Diabetes Medicines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetes Medicines Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetes Medicines Sales (2021-2032) & (K Units) Figure 5. Global Diabetes Medicines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Diabetes Medicines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global Diabetes Medicines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Diabetes Medicines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Diabetes Medicines Sales Market Share by Type (2021-2032) Figure 13. Global Diabetes Medicines Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Diabetes Medicines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Diabetes Medicines Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Retail Pharmacy Image Figure 18. Global Diabetes Medicines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Diabetes Medicines Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Diabetes Medicines Sales Market Share by Application (2021-2032) Figure 21. Global Diabetes Medicines Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Diabetes Medicines Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Diabetes Medicines Revenue Market Share by Application (2021-2032) Figure 24. North America Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Diabetes Medicines Sales Market Share by Country (2021-2032) Figure 26. U.S. Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Diabetes Medicines Sales Market Share by Country (2021-2032) Figure 31. Germany Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Diabetes Medicines Sales Market Share by Country (2021-2032) Figure 38. China Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Diabetes Medicines Sales Market Share by Country (2021-2032) Figure 46. Brazil Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Diabetes Medicines Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Diabetes Medicines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Diabetes Medicines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Diabetes Medicines Revenue (2021-2032) & (US$ Million) Figure 57. North America Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Diabetes Medicines Revenue (2021-2032) & (US$ Million) Figure 59. Europe Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Diabetes Medicines Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Diabetes Medicines Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Diabetes Medicines Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Diabetes Medicines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Biocon
  • Boehringer Ingelheim
  • Geropharm
  • Wockhardt
  • AstraZeneca
  • bayer
  • Ganli Pharmaceutical
  • Jiangsu Wanbang
  • Conker Pharmaceuticals
  • Eli Lilly
  • United Pharmaceuticals
  • Merck Serono
  • Merck
  • Novo Nordisk
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Tonghua Dongbao
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diabetes Medicines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diabetes Medicines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Diabetes Medicines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Diabetes Medicines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Diabetes Medicines Market Dynamics
  1. 2.1 Diabetes Medicines Industry Trends
  2. 2.2 Diabetes Medicines Industry Drivers
  3. 2.3 Diabetes Medicines Industry Opportunities and Challenges
  4. 2.4 Diabetes Medicines Industry Restraints
3 Diabetes Medicines Market by Manufacturers
  1. 3.1 Global Diabetes Medicines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Diabetes Medicines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Diabetes Medicines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Diabetes Medicines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diabetes Medicines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Diabetes Medicines Manufacturers, Product Type & Application
  7. 3.7 Global Diabetes Medicines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diabetes Medicines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diabetes Medicines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diabetes Medicines Tier 1, Tier 2, and Tier 3
4 Diabetes Medicines Market by Type
  1. 4.1 Diabetes Medicines Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Diabetes Medicines Sales by Type
  5. 4.2.1 Global Diabetes Medicines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diabetes Medicines Sales by Type (2021-2032)
  7. 4.2.3 Global Diabetes Medicines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Diabetes Medicines Revenue by Type
  9. 4.3.1 Global Diabetes Medicines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Diabetes Medicines Revenue by Type (2021-2032)
  11. 4.3.3 Global Diabetes Medicines Revenue Market Share by Type (2021-2032)
5 Diabetes Medicines Market by Application
  1. 5.1 Diabetes Medicines Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Diabetes Medicines Sales by Application
  5. 5.2.1 Global Diabetes Medicines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Diabetes Medicines Sales by Application (2021-2032)
  7. 5.2.3 Global Diabetes Medicines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Diabetes Medicines Revenue by Application
  9. 5.3.1 Global Diabetes Medicines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Diabetes Medicines Revenue by Application (2021-2032)
  11. 5.3.3 Global Diabetes Medicines Revenue Market Share by Application (2021-2032)
6 Global Diabetes Medicines Sales by Region
  1. 6.1 Global Diabetes Medicines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetes Medicines Sales by Region (2021-2032)
  3. 6.2.1 Global Diabetes Medicines Sales by Region (2021-2026)
  4. 6.2.2 Global Diabetes Medicines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Diabetes Medicines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Diabetes Medicines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Diabetes Medicines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Diabetes Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Diabetes Medicines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Diabetes Medicines Revenue by Region
  1. 7.1 Global Diabetes Medicines Revenue by Region
  2. 7.1.1 Global Diabetes Medicines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Diabetes Medicines Revenue by Region (2021-2026)
  4. 7.1.3 Global Diabetes Medicines Revenue by Region (2027-2032)
  5. 7.1.4 Global Diabetes Medicines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Diabetes Medicines Revenue (2021-2032)
  8. 7.2.2 North America Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Diabetes Medicines Revenue (2021-2032)
  11. 7.3.2 Europe Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Diabetes Medicines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Diabetes Medicines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Diabetes Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocon
  2. 8.1.1 Biocon Company Information
  3. 8.1.2 Biocon Business Overview
  4. 8.1.3 Biocon Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biocon Diabetes Medicines Product Portfolio
  6. 8.1.5 Biocon Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim Diabetes Medicines Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Geropharm
  14. 8.3.1 Geropharm Company Information
  15. 8.3.2 Geropharm Business Overview
  16. 8.3.3 Geropharm Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Geropharm Diabetes Medicines Product Portfolio
  18. 8.3.5 Geropharm Recent Developments
  19. 8.4 Wockhardt
  20. 8.4.1 Wockhardt Company Information
  21. 8.4.2 Wockhardt Business Overview
  22. 8.4.3 Wockhardt Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Wockhardt Diabetes Medicines Product Portfolio
  24. 8.4.5 Wockhardt Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Diabetes Medicines Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 bayer
  32. 8.6.1 bayer Company Information
  33. 8.6.2 bayer Business Overview
  34. 8.6.3 bayer Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 bayer Diabetes Medicines Product Portfolio
  36. 8.6.5 bayer Recent Developments
  37. 8.7 Ganli Pharmaceutical
  38. 8.7.1 Ganli Pharmaceutical Company Information
  39. 8.7.2 Ganli Pharmaceutical Business Overview
  40. 8.7.3 Ganli Pharmaceutical Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ganli Pharmaceutical Diabetes Medicines Product Portfolio
  42. 8.7.5 Ganli Pharmaceutical Recent Developments
  43. 8.8 Jiangsu Wanbang
  44. 8.8.1 Jiangsu Wanbang Company Information
  45. 8.8.2 Jiangsu Wanbang Business Overview
  46. 8.8.3 Jiangsu Wanbang Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Wanbang Diabetes Medicines Product Portfolio
  48. 8.8.5 Jiangsu Wanbang Recent Developments
  49. 8.9 Conker Pharmaceuticals
  50. 8.9.1 Conker Pharmaceuticals Company Information
  51. 8.9.2 Conker Pharmaceuticals Business Overview
  52. 8.9.3 Conker Pharmaceuticals Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Conker Pharmaceuticals Diabetes Medicines Product Portfolio
  54. 8.9.5 Conker Pharmaceuticals Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Diabetes Medicines Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 United Pharmaceuticals
  62. 8.11.1 United Pharmaceuticals Company Information
  63. 8.11.2 United Pharmaceuticals Business Overview
  64. 8.11.3 United Pharmaceuticals Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 United Pharmaceuticals Diabetes Medicines Product Portfolio
  66. 8.11.5 United Pharmaceuticals Recent Developments
  67. 8.12 Merck Serono
  68. 8.12.1 Merck Serono Company Information
  69. 8.12.2 Merck Serono Business Overview
  70. 8.12.3 Merck Serono Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Serono Diabetes Medicines Product Portfolio
  72. 8.12.5 Merck Serono Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck Diabetes Medicines Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Novo Nordisk
  80. 8.14.1 Novo Nordisk Company Information
  81. 8.14.2 Novo Nordisk Business Overview
  82. 8.14.3 Novo Nordisk Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Novo Nordisk Diabetes Medicines Product Portfolio
  84. 8.14.5 Novo Nordisk Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Diabetes Medicines Product Portfolio
  90. 8.15.5 Novartis Recent Developments
  91. 8.16 Johnson & Johnson
  92. 8.16.1 Johnson & Johnson Company Information
  93. 8.16.2 Johnson & Johnson Business Overview
  94. 8.16.3 Johnson & Johnson Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Johnson & Johnson Diabetes Medicines Product Portfolio
  96. 8.16.5 Johnson & Johnson Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Diabetes Medicines Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Tonghua Dongbao
  104. 8.18.1 Tonghua Dongbao Company Information
  105. 8.18.2 Tonghua Dongbao Business Overview
  106. 8.18.3 Tonghua Dongbao Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Tonghua Dongbao Diabetes Medicines Product Portfolio
  108. 8.18.5 Tonghua Dongbao Recent Developments
  109. 8.19 Takeda
  110. 8.19.1 Takeda Company Information
  111. 8.19.2 Takeda Business Overview
  112. 8.19.3 Takeda Diabetes Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Takeda Diabetes Medicines Product Portfolio
  114. 8.19.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diabetes Medicines Value Chain Analysis
  2. 9.1.1 Diabetes Medicines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diabetes Medicines Production Mode & Process
  6. 9.2 Diabetes Medicines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diabetes Medicines Distributors
  9. 9.2.3 Diabetes Medicines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst